PM14 Administered Intravenously to Patients with Advanced Solid Tumors
Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid Tumors
Sponsor: PharmaMar
This PHASE1 trial investigates Advanced Solid Tumor and is currently actively recruiting participants. PharmaMar leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Jan 2025 — Present [monthly]
Recruiting PHASE1
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
Status: Unknown Status → Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jun 2022 — Jun 2024 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Nov 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE1
First recorded
Sep 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- PharmaMar
For direct contact, visit the study record on ClinicalTrials.gov .